Prevention & Control Clinical Trial
— SORCOSOfficial title:
Substantivity of Mouthrinse Formulations Containing Cetylpyridinium Chloride and O-cymen-5-Ol Compared to Placebo on Salivary Microbiota
Verified date | May 2022 |
Source | University of Barcelona |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A desirable quality of mouthrinses is substantivity an intrinsic feature of some molecules. Substantivity requires the adsorption of the agent on the oral surfaces and subsequently antimicrobial activity bacteriostatic along following hours. This work aims to quantitatively determine the substantivity of (i) a single o-Cymen-5-ol plus CPC oral rinse, (ii) a, CPC oral rinse and (iii) a o-Cymen-5-ol mouthwash on the salivary microbiota up to 4 h after their application.
Status | Completed |
Enrollment | 16 |
Est. completion date | February 3, 2022 |
Est. primary completion date | January 25, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion criteria: 1. adult age (>18 y/o) 2. good oral helath status 3. minimum 24 evaluable teeth 4. periodontal pockets =3 mm 5. absence of caries & periodontal haemorrage Exclusion Criteria: 1. smokers 2. prosthesis or orthodontic devices 3. Sjögren syndrome 4. Antibiotic treatment in the last three months 5. Systemic disease with alteration in the production and/or composition of the saliva |
Country | Name | City | State |
---|---|---|---|
Spain | University of Barcelona. Campus Bellvitge | Hospitalet de Llobregat | Barcelona |
Lead Sponsor | Collaborator |
---|---|
University of Barcelona |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Preliminary experiments | Measure of surviving bacteria by fluorimetry and confocal microscopy (Live & dead) | one month | |
Secondary | Substantivity of mouthrinse formulations containing Cetylpyridinium Chloride and O-cymen-5-Ol (single and combined) compared to Placebo on salivary microbiota | Measure of surviving bacteria by fluorimetry and confocal microscopy (Live & dead) rinses plus placebo | up to three months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04062578 -
Effects Provided by a Physiotherapy Treatment Preventing Lower Extremity Injuries in Female Football Players
|
N/A | |
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Completed |
NCT00793455 -
Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders
|
N/A | |
Completed |
NCT00563264 -
KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
|
N/A | |
Completed |
NCT05261152 -
S. Boulardii in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults With Respiratory Tract Infections
|
Phase 4 | |
Completed |
NCT02165709 -
Cohort Study of Risk Reducing Salpingectomy
|
N/A | |
Recruiting |
NCT06164600 -
Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children
|
Phase 2 | |
Completed |
NCT01776424 -
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
|
Phase 3 | |
Enrolling by invitation |
NCT02580279 -
Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy
|
Phase 2 | |
Recruiting |
NCT01747278 -
Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT02577393 -
Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy
|
Phase 2 | |
Withdrawn |
NCT01137591 -
Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever
|
N/A |